ClinicalTrials.gg
CompletedNCT04773353IRISUpdated Jan 24, 2025

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women

A Phase 3 interventional study of Follitropin Delta (FE 999049) and Follitropin Alfa (GONAL-F) in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 12 sites in India. Open to female participants aged 21 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
21 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
7th of 13
220 · median 220
Started
2021
with 1 other
Phase 3
6 of 13
none open now
Registered
9th of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 9th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 21 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Forms signed prior to screening evaluations.
  • In good physical and mental health as judged by the investigator.
  • Indian (i.e., possessing an Indian identification card and having native Indian parents) pre-menopausal females between the ages of 21 and 40 years. The participants must be at least 21 years (including the 21st birthday) when they sign the informed consent and no more than 40 years (up to the day before the 41st birthday) at the time of randomization.
  • Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II (defined by the revised American Society for Reproductive Medicine [ASRM] classification, 1996) or with partners diagnosed with male factor infertility, eligible for in vitro fertilization (IVF) and/or ICSI using fresh or frozen ejaculated sperm from male partner or sperm donor.
  • Infertility for at least one year before randomization for participants \<35 years or for at least 6 months for participants ≥35 years (not applicable in case of tubal or severe male factor infertility).
  • The trial cycle will be the participant's first controlled ovarian stimulation cycle for IVF/ICSI.
  • Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
  • Hysterosalpingography, hysteroscopy, saline infusion sonography, or transvaginal ultrasound documenting a uterus consistent with expected normal function (e.g. no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are associated with a reduced chance of pregnancy) within 1 year prior to randomization.
  • Transvaginal ultrasound documenting presence and adequate visualization of both ovaries, without evidence of significant abnormality (e.g., enlarged ovaries which would contraindicate the use of gonadotropins) and normal adnexa (e.g., no hydrosalpinx) within 1 year prior to randomization. Both ovaries must be accessible for oocyte retrieval.
  • Early follicular phase (cycle day 2-4) serum levels of FSH between 1 and 15 IU/L (results obtained within 3 months prior to randomization).
  • Negative serum Surface Antigen (HBsAg), Virus (HCV) and (HIV) antibody tests within 1 year prior to randomization.
  • (BMI) between 17.5 and 32.0 kg/m\^2 (both inclusive) at screening.
  • Willing to accept transfer of 1-2 embryos.

Exclusion criteria

Exclusion Criteria:

  • Known endometriosis stage III-IV (defined by the revised ASRM classification, 1996).
  • One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound prior to randomization on stimulation day 1 (puncture of cysts is allowed prior to randomization).
  • Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy [excluding ectopic pregnancy] and before Week 24 of pregnancy).
  • Known abnormal karyotype of participant or of her partner/sperm donor, as applicable, depending on source of sperm used for insemination in this trial.
  • Any known systemic disease (e.g., insulin-dependent diabetes).
  • Known inherited or acquired thrombophilia disease.
  • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
  • Known porphyria.
  • Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) with the exception of controlled thyroid function disease.
  • Known presence of anti-FSH antibodies (based on the information available in the participant's medical records).
  • Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotropins.
  • Known moderate or severe impairment of renal or hepatic function.
  • Any abnormal finding of clinical chemistry, haematology or vital signs at screening which is clinically significant as judged by the investigator.
  • Currently breast-feeding.
  • Undiagnosed vaginal bleeding.
  • Known abnormal cervical cytology of clinical significance observed within 3 years prior to randomization (unless the clinical significance has been resolved).
  • Findings at the gynecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g., congenital uterine abnormalities or retained intrauterine device.
  • Pregnancy (negative urinary pregnancy tests must be documented at screening and prior to randomization) or to pregnancy.
  • Known current active pelvic inflammatory disease.
  • Use of fertility modifiers during the last menstrual cycle before randomization, including dehydroepiandrosterone (DHEA), metformin or cycle programming with oral , progestogen or estrogen preparations.
  • Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle before randomization.
  • Known history of chemotherapy (except for gestational conditions) or radiotherapy.
  • Current or past (1 year prior to randomization) abuse of alcohol or drugs.
  • Current (last month) intake of more than 14 units of alcohol per week.
  • Current or past (3 months prior to randomization) smoking habit of more than 10 cigarettes per day.
  • to any active ingredient or in the medicinal products used in the trial.
  • Previous participation in the trial.
  • Use of any non-registered drugs during the last 3 months prior to randomization.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Follitropin Delta (FE 999049)

    Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection

    Drug: Follitropin Delta (FE 999049)

  • Experimental
    Follitropin Alfa (GONAL-F)

    rFSH. Follitropin alfa for subcutaneous injection

    Drug: Follitropin Alfa (GONAL-F)

Interventions

  • FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.

    Also known as: REKOVELLE

  • GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.

    Also known as: GONAL-F

06

What researchers measure

Primary outcomes

  1. Ongoing pregnancy rate

    Ongoing pregnancy is defined as at least one intrauterine viable fetus 10-11 weeks after embryo transfer.

    Time frame: 10-11 weeks after embryo transfer

Secondary outcomes

  1. Positive beta human chorionic gonadotropin (βhCG) rate

    Positive βhCG is defined as positive serum βhCG test 13-15 days after embryo transfer.

    Time frame: 13-15 days after embryo transfer

  2. Clinical pregnancy rate

    Clinical pregnancy is defined as at least one gestational sac 5-6 weeks after embryo transfer.

    Time frame: 5-6 weeks after embryo transfer

  3. Vital pregnancy rate

    Vital pregnancy is defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after embryo transfer.

    Time frame: 5-6 weeks after embryo transfer

  4. Implantation rate

    Implantation rate is defined as the number of gestational sacs 5-6 weeks after transfer divided by number of embryos transferred.

    Time frame: 5-6 weeks after embryo transfer

  5. Ongoing implantation rate

    Ongoing implantation rate is defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of embryos transferred.

    Time frame: 10-11 weeks after embryo transfer

  6. Proportion of subjects with extreme ovarian responses

    Extreme ovarian response is defined as \<4, ≥15 or ≥20 oocytes retrieved.

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  7. Proportion of subjects with early ovarian hyperstimulation syndrome (OHSS) (including OHSS of moderate/severe grade) and/or preventive interventions for early OHSS

    The proportion of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS will be presented.

    Time frame: ≤9 days after triggering of final follicular maturation

  8. Proportion of subjects with cycle cancellation due to poor or excessive ovarian response or embryo transfer cancellation due to excessive ovarian response / OHSS risk

    The proportion of participants with cycle cancellation due to poor or excessive ovarian response or embryo transfer cancellation due to excessive ovarian response / OHSS risk will be presented.

    Time frame: At end-of-stimulation (up to 20 stimulation days) or transfer visit

  9. Number of follicles on stimulation Day 6

    Counted by ultrasound for the right and left ovary.

    Time frame: On stimulation Day 6

  10. Number of follicles at end-of-stimulation

    Counted by ultrasound for the right and left ovary.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  11. Size of follicles on stimulation Day 6

    Measured by ultrasound for the right and left ovary.

    Time frame: On stimulation Day 6

  12. Size of follicles at end-of-stimulation

    Measured by ultrasound for the right and left ovary.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  13. Number of oocytes retrieved

    The number of oocytes retrieved will be recorded at the oocyte retrieval visit.

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  14. Proportion of subjects with <4, 4-7, 8-14, 15-19 and ≥20 oocytes retrieved

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

  15. Percentage of metaphase II oocytes (only applicable for those inseminated using intracytoplasmic sperm injection [ICSI])

    The percentage of metaphase II oocytes to oocytes retrieved for participants where all oocytes were inseminated using ICSI will be presented.

    Time frame: On day of oocyte retrieval (up to 22 days after stimulation)

  16. Fertilisation rate

    The fertilisation rate is defined as the number of fertilized oocytes with 2 pronuclei divided by the number of oocytes retrieved.

    Time frame: On Day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  17. Number and quality of embryos on day 3 after oocyte retrieval

    The total number of embryos and the number of good-quality embryos will be counted on Day 3. A good-quality embryo is defined as an embryo with ≥6 blastomeres and ≤20% fragmentation, without signs of multinucleation.

    Time frame: On Day 3 after oocyte retrieval (up to 25 days after start of stimulation)

  18. Circulating concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)

    Blood samples for analysis of circulating concentrations of FSH and LH will be drawn.

    Time frame: On stimulation day 6

  19. Circulating concentrations of estradiol

    Blood samples for analysis of circulating concentrations of estradiol will be drawn.

    Time frame: On stimulation day 6

  20. Circulating concentrations of progesterone

    Blood samples for analysis of circulating concentrations of progesterone will be drawn.

    Time frame: On stimulation day 6

  21. Circulating concentrations of inhibin A and inhibin B

    Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn.

    Time frame: On stimulation day 6

  22. Circulating concentrations of FSH and LH

    Blood samples for analysis of circulating concentrations of FSH and LH will be drawn.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  23. Circulating concentrations of estradiol

    Blood samples for analysis of circulating concentrations of estradiol will be drawn.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  24. Circulating concentrations of progesterone

    Blood samples for analysis of circulating concentrations of progesterone will be drawn.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  25. Circulating concentrations of inhibin A and inhibin B

    Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  26. Total gonadotropin dose

    The total gonadotropin dose will be recorded.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  27. Number of stimulation days

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  28. Proportion of subjects with investigator-requested gonadotropin dose adjustments

    The decreases and increases of the gonadotropin dose will be captured during the stimulation period.

    Time frame: From stimulation Day 6 to end-of-stimulation (up to 20 stimulation days)

  29. Number of events and intensity of adverse events

    Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)

  30. Changes from baseline in circulating levels of clinical chemistry parameters: Albumin and Total protein

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Albumin and Total protein.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  31. Changes from baseline in circulating levels of clinical chemistry parameters: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase, Gamma-glutamyl transpeptidase

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase and Gamma-glutamyl transpeptidase.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  32. Changes from baseline in circulating levels of clinical chemistry parameters: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium, Uric acid

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium and Uric acid.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  33. Changes from baseline in circulating levels of clinical chemistry parameters: Bilirubin direct, Bilirubin, Creatinine

    Blood samples will be collected for the analysis of clinical chemistry parameters including: Bilirubin direct, Bilirubin and Creatinine.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  34. Changes from baseline in circulating levels of clinical chemistry parameters: Lactate dehydrogenase

    Blood samples will be collected for the analysis of clinical chemistry parameter including: Lactate dehydrogenase.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  35. Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-stimulation

    Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  36. Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-trial

    Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

    Time frame: At end-of-trial (up to approximately 5.5 months)

  37. Changes from baseline in circulating levels of clinical haematology parameters: Red blood cells, Red blood cells morphology

    Blood samples will be collected for the analysis of clinical haematology including: Red blood cells and Red blood cell morphology.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  38. Changes from baseline in circulating levels of clinical haematology parameters: White blood cells, White blood cell morphology, Platelets

    Blood samples will be collected for the analysis of clinical haematology including: White blood cells, White blood cell morphology and Platelets.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  39. Changes from baseline in circulating levels of clinical haematology parameters: Haemoglobin

    Blood samples will be collected for the analysis of clinical haematology parameter including: Haemoglobin.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  40. Changes from baseline in circulating levels of clinical haematology parameters: Haematocrit

    Blood samples will be collected for the analysis of clinical haematology parameter including: Haematocrit.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  41. Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Volume

    Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Volume.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  42. Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Haemoglobin

    Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Haemoglobin.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  43. Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Hemoglobin Concentration

    Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Hemoglobin Concentration.

    Time frame: From screening up to end-of-trial (up to approximately 5.5 months)

  44. Proportion of subjects with markedly abnormal changes from baseline in haematology parameters at end-of-stimulation

    Defined as number of participants with at least one markedly abnormal changes in haematology parameters (as assessed by investigator) will be reported. Haematology parameters include: red blood cells, red blood cell morphology, white blood cells, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  45. Proportion of subjects with markedly abnormal changes from baseline in haematology parameters end-of-trial

    Defined as number of participants with at least one markedly abnormal changes in haematology parameters (as assessed by investigator) will be reported. Haematology parameters include: red blood cells, red blood cell morphology, white blood cells, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

    Time frame: At end-of-trial (up to approximately 5.5 months)

  46. Frequency of injection site reactions (redness, pain, itching, swelling and bruising)

    Assessed by the participant during the stimulation period. Participants will self-assess injection site reactions (redness, pain, itching, swelling, and bruising) immediately, 30 minutes and 24 hours after each injection.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  47. Intensity of injection site reactions

    Assessed by the participant during the stimulation period as mild, moderate or severe. Participants will be tabulated according to the highest severity of their reported injection site reactions.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  48. Frequency of immune-related adverse events

    All adverse events reported in the trial will be analyzed to identify those that are potentially immune-related. They will be tabulated using the Standardised Medical Dictionary for Regulatory Activities \[MedDRA\] Queries (SMQs).

    Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)

  49. Intensity of immune-related adverse events

    Will be categorised as mild, moderate or severe.

    Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)

  50. Proportion of subjects with cycle cancellations due to an adverse event, including immune-related adverse events, or due to technical malfunctions of the pre-filled injection pen

    For each participant the reason for cycle cancellation will be recorded.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  51. Proportion of subjects with late OHSS (including OHSS of moderate/severe grade)

    Late OHSS is defined as OHSS with onset \>9 days after triggering of final follicular maturation. The proportion of participants with late OHSS, and late OHSS of moderate or severe grade will be presented.

    Time frame: >9 days after triggering of final follicular maturation

  52. Proportion of subjects with OHSS (early and/or late) and/or preventive interventions for early OHSS

    The proportion of participants with early and/or late OHSS and/or preventive interventions for early OHSS will be presented.

    Time frame: >9 days after triggering of final follicular maturation

  53. Percentage of subjects with multi-fetal gestation, biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins

    The percentage of participants with each of these events will be reported.

    Time frame: 10-11 weeks after transfer

  54. Technical malfunctions of the pre-filled injection pen

    Participants will report any technical malfunctions of the pre-filled injection pen. Percentage of participants with confirmed technical malfunctions will be presented.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

07

Study locations

12 sites
  • Ferring Investigational Site
    Ahmedabad, Gujarat, India
  • Ferring Investigational Site
    Anand, Gujarat, India
  • Ferring Investigational Site
    Nashik, Maharashtra, India
  • Ferring Investigational Site
    Pune, Mumbai, India
  • Ferring Investigational Site
    Varanasi, New Delhi, India
  • Ferring Investigational Site
    Chennai, Tamil Nadu, India
  • Ferring Investigational Site
    Coimbatore, Tamil Nadu, India
  • Ferring Investigational Site
    Secunderabad, Telangana, India
  • Ferring Investigational Site
    Lucknow, Uttar Pradesh, India
  • Ferring Investigational Site
    Bangalore, India
  • Ferring Investigational Site
    Kolhapur, India
  • Ferring Investigational Site
    New Delhi, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Dec 2023, 24 months.

Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 24 months is above that.

Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 26, 2021
StartActual
Dec 3, 2021
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04773353
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Dec 3, 2021
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Last update
Jan 24, 2025

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Follitropin delta · Follitropin alfa

Start the discussion